Prosecution Insights
Prosecution Insights
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §102 only | 1 (17%) |
| No statute on record | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DIBRINO, MARIANNE | 1 | 43.3% | +41.2% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.3% |
| QIAN, CELINE X | 1 | 47.9% | +16.8% |
| VAN DRUFF, SYDNEY | 1 | 57.2% | +28.5% |
| YAO, LEI | 1 | 60.0% | +65.6% |
| PATTERSON, SARAH COOPER | 1 | 58.6% | +56.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17927501 | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof | VAN DRUFF, SYDNEY | 80d overdue |
| 18107244 | MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF | DIBRINO, MARIANNE | 79d overdue |
| 17490516 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | PATTERSON, SARAH COOPER | 72d overdue |
| 18107265 | MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | HUYNH, PHUONG N | 30d overdue |
| 18005813 | T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | QIAN, CELINE X | 18d overdue |
| 17927477 | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof | YAO, LEI | 53d |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1637 | 1 |
| 1643 | 1 |
| 1642 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18107244 | MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF | DIBRINO, MARIANNE | 1641 | §102 | Non-Final OA | 79d overdue | Pending | Feb 08, 2023 |
| 18107265 | MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | HUYNH, PHUONG N | 1641 | §103 | Non-Final OA | 30d overdue | Pending | Feb 08, 2023 |
| 18005813 | T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof | QIAN, CELINE X | 1637 | Other | Non-Final OA | 18d overdue | Pending | Jan 17, 2023 |
| 17927501 | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof | VAN DRUFF, SYDNEY | 1643 | §103 | Non-Final OA | 80d overdue | Pending | Nov 23, 2022 |
| 17927477 | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof | YAO, LEI | 1642 | Other | Non-Final OA | 53d | Pending | Nov 23, 2022 |
| 17490516 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | PATTERSON, SARAH COOPER | 1675 | Other | Final Rejection | 72d overdue | Pending | Sep 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial